Logo image of AEON

AEON BIOPHARMA INC (AEON) Stock Fundamental Analysis

USA - NYSE Arca - NYSEARCA:AEON - US00791X2099 - Common Stock

1.1 USD
+0.02 (+1.85%)
Last: 12/31/2025, 8:04:00 PM
1.1629 USD
+0.06 (+5.72%)
After Hours: 12/31/2025, 8:04:00 PM
Fundamental Rating

1

Overall AEON gets a fundamental rating of 1 out of 10. We evaluated AEON against 0 industry peers in the Unkown industry. AEON has a bad profitability rating. Also its financial health evaluation is rather negative. AEON has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year AEON has reported negative net income.
AEON had a negative operating cash flow in the past year.
AEON had negative earnings in 4 of the past 5 years.
In the past 5 years AEON always reported negative operating cash flow.
AEON Yearly Net Income VS EBIT VS OCF VS FCFAEON Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M -200M -300M

1.2 Ratios

Industry RankSector Rank
ROA -14.03%
ROE N/A
ROIC N/A
ROA(3y)-1589.97%
ROA(5y)-1126.87%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AEON Yearly ROA, ROE, ROICAEON Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -2K -4K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for AEON so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AEON Yearly Profit, Operating, Gross MarginsAEON Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 2K 4K

More info and screens

1

2. Health

2.1 Basic Checks

AEON has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, AEON has less shares outstanding
Compared to 1 year ago, AEON has a worse debt to assets ratio.
AEON Yearly Shares OutstandingAEON Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M
AEON Yearly Total Debt VS Total AssetsAEON Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -53.66, we must say that AEON is in the distress zone and has some risk of bankruptcy.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -53.66
ROIC/WACCN/A
WACCN/A
AEON Yearly LT Debt VS Equity VS FCFAEON Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M -100M -150M

2.3 Liquidity

A Current Ratio of 1.12 indicates that AEON should not have too much problems paying its short term obligations.
AEON has a Quick Ratio of 1.12. This is a normal value and indicates that AEON is financially healthy and should not expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 1.12
Quick Ratio 1.12
AEON Yearly Current Assets VS Current LiabilitesAEON Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 99.01% over the past year.
The Earnings Per Share has been growing by 56.13% on average over the past years. This is a very strong growth
EPS 1Y (TTM)99.01%
EPS 3YN/A
EPS 5Y56.13%
EPS Q2Q%95.6%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

AEON is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -49.88% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-101.3%
EPS Next 2Y-41.9%
EPS Next 3Y-26.16%
EPS Next 5Y-49.88%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AEON Yearly Revenue VS EstimatesAEON Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2027 2028 2029 2030 50M 100M 150M 200M
AEON Yearly EPS VS EstimatesAEON Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 0 20 -20 40 -40 -60 -80

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AEON reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AEON is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AEON Price Earnings VS Forward Price EarningsAEON Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AEON Per share dataAEON EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -1 -2 -3 -4 -5

4.3 Compensation for Growth

AEON's earnings are expected to decrease with -26.16% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-41.9%
EPS Next 3Y-26.16%

More info and screens

0

5. Dividend

5.1 Amount

AEON does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

AEON BIOPHARMA INC

NYSEARCA:AEON (12/31/2025, 8:04:00 PM)

After market: 1.1629 +0.06 (+5.72%)

1.1

+0.02 (+1.85%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)11-14 2025-11-14/bmo
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner Change11.3%
Ins OwnersN/A
Ins Owner Change0%
Market Cap40.87M
Revenue(TTM)N/A
Net Income(TTM)-1.64M
Analysts82.5
Price Target6.22 (465.45%)
Short Float %0.58%
Short Ratio0.27
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-15.28%
PT rev (3m)-15.28%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-33.66%
EPS NY rev (3m)-2.27%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-5.98
EYN/A
EPS(NY)-0.71
Fwd EYN/A
FCF(TTM)-0.37
FCFYN/A
OCF(TTM)-0.37
OCFYN/A
SpS0
BVpS-0.43
TBVpS-0.43
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -14.03%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-1589.97%
ROA(5y)-1126.87%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.12
Quick Ratio 1.12
Altman-Z -53.66
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.01%
EPS 3YN/A
EPS 5Y56.13%
EPS Q2Q%95.6%
EPS Next Y-101.3%
EPS Next 2Y-41.9%
EPS Next 3Y-26.16%
EPS Next 5Y-49.88%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-110.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y67.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y66.99%
OCF growth 3YN/A
OCF growth 5YN/A

AEON BIOPHARMA INC / AEON FAQ

Can you provide the ChartMill fundamental rating for AEON BIOPHARMA INC?

ChartMill assigns a fundamental rating of 1 / 10 to AEON.


What is the valuation status of AEON BIOPHARMA INC (AEON) stock?

ChartMill assigns a valuation rating of 0 / 10 to AEON BIOPHARMA INC (AEON). This can be considered as Overvalued.


What is the profitability of AEON stock?

AEON BIOPHARMA INC (AEON) has a profitability rating of 0 / 10.